Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies

Anti-EGFR mAb (cetuximab or panitumumab) and anti-VEGF mAb (bevacizumab) are the two main targeted agents available for RAS wild-type (WT) metastatic colorectal cancer (mCRC) treatment. Nonetheless, three head-to-head clinical trials evaluating anti-EGFR mAb vs -VEGF mAb in first-line treatment fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Datian, Gu, Kaikai, Wang, Huiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388996/
https://www.ncbi.nlm.nih.gov/pubmed/30863179
http://dx.doi.org/10.2147/CMAR.S196170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388996/
https://www.ncbi.nlm.nih.gov/pubmed/30863179
http://dx.doi.org/10.2147/CMAR.S196170

Ejemplares similares